CA - HLS Therapeutics GAAP EPS of -$0.18 revenue of $14.8M misses by $1.24M
2023-05-11 13:11:19 ET
- HLS Therapeutics press release ( OTCPK:HLTRF ): Q1 GAAP EPS of -$0.18.
- Revenue of $14.8M (+1.4% Y/Y) misses by $1.24M .
-
VASCEPA 2023 OUTLOOK
The Company expects revenue growth for Vascepa to increase over the course of the year. The positive impact from strong prescription growth in Q1 2023 was partly offset by the payer mix being more weighted to public plans than was expected. As a result of the near-term impact of this payer mix, HLS is now guiding to the low end of its previously issued C$22-28 million revenue range for Vascepa in 2023.
For further details see:
HLS Therapeutics GAAP EPS of -$0.18, revenue of $14.8M misses by $1.24M